Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 189-194

  Pistorius, Steffen ^a   Kruger, Stefan ^a   Hohl, Ruth ^a   Plaschke, Jens ^a   Distler, Wolfgang ^a   Saeger, Hans Detlev ^a   Schackert, Hans Konrad ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Endometrial cancer; Hereditary nonpolyposis colorectal cancer (HNPCC); Prophylactic hysterectomy

Indexed keywords

DNA MINISATELLITE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; CANCER STAGING; COLON POLYPOSIS; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MISMATCH REPAIR; OVARIECTOMY; OVARY CANCER; POSTMENOPAUSE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYSTERECTOMY; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33745890649     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.032     Document Type: Article

References (66)

1. Vasen H.F., Mecklin J.P., Khan P.M., Lynch H.T., and The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum 34 (1991) 424-425
2. Vasen H.F., Watson P., Mecklin J.P., and Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
3. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368 (1994) 258-261
4. Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Rao M.R., Morrison P., et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics 24 (1994) 516-526
5. Fishel R., Lescoe M.K., Rao M.R., Copeland N.G., Jenkins N.A., Garber J., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (1993) 1027-1038
6. Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75 (1993) 1215-1225
7. Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., Watson P., et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat. Med. 2 (1996) 169-174
8. Miyaki M., Konishi M., Tanaka K., Kikuchi-Yanoshita R., Muraoka M., Yasuno M., et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat. Genet. 17 (1997) 271-272
9. Nicolaides N.C., Papadopoulos N., Liu B., Wei Y.F., Carter K.C., Ruben S.M., et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371 (1994) 75-80
10. Papadopoulos N., Nicolaides N.C., Wei Y.F., Ruben S.M., Carter K.C., Rosen C.A., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 263 (1994) 1625-1629
11. Kolodner R.D., Hall N.R., Lipford J., Kane M.F., Morrison P.T., Finan P.J., et al. Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. Cancer Res. 55 (1995) 242-248
12. Box J.C., Rodriguez-Bigas M.A., Weber T.K., and Petrelli N.J. Clinical implications of multiple colorectal carcinomas in hereditary nonpolyposis colorectal carcinoma. Dis. Colon Rectum 42 (1999) 717-721
13. Vasen H.F., Nagengast F.M., and Khan P.M. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 345 (1995) 1183-1184
14. Dunlop M.G., Farrington S.M., Carothers A.D., Wyllie A.H., Sharp L., Burn J., et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Mol. Genet. 6 (1997) 105-110
15. Aarnio M., Mecklin J.P., Aaltonen L.A., Nystrom-Lahti M., and Jarvinen H.J. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64 (1995) 430-433
16. Aarnio M., Sankila R., Pukkala E., Salovaara R., Aaltonen L.A., de la Chapelle A., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int. J. Cancer 81 (1999) 214-218
17. Lynch H.T. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers?. Dis. Colon Rectum 39 (1996) 109-110
18. Lynch H.T., and Lynch J.F. 25 years of HNPCC. Anticancer Res. 14 (1994) 1617-1624
19. Rodriguez-Bigas M.A., Vasen H.F., Pekka-Mecklin J., Myrhoj T., Rozen P., Bertario L., et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann. Surg. 225 (1997) 202-207
20. Vasen H.F., Wijnen J.T., Menko F.H., Kleibeuker J.H., Taal B.G., Griffioen G., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 (1996) 1020-1027
21. Sijmons R.H., Kiemeney L.A., Witjes J.A., and Vasen H.F. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J. Urol. 160 (1998) 466-470
22. Watson P., and Lynch H.T. Cancer risk in mismatch repair gene mutation carriers. Fam. Can. 1 (2001) 57-60
23. Watson P., Vasen H.F., Mecklin J.P., Jarvinen H., and Lynch H.T. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am. J. Med. 96 (1994) 516-520
24. Rijcken F.E., Mourits M.J., Kleibeuker J.H., Hollema H., and van der Zee A.G. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 91 (2003) 74-80
25. Watson P., Butzow R., Lynch H.T., Mecklin J.P., Jarvinen H.J., Vasen H.F., et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 82 (2001) 223-228
26. Brown G.J., St John D.J., Macrae F.A., and Aittomaki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol. Oncol. 80 (2001) 346-349
27. Schmiegel W., Adler G., Fruhmorgen P., Folsch U., Graeven U., Layer P., et al. Colorectal carcinoma: prevention and early detection in an asymptomatic population-prevention in patients at risk-Endoscopic diagnosis, therapy and after-care of polyps and carcinomas. German Society of Digestive and Metabolic Diseases/Study Group for Gastrointestinal Oncology. Z. Gastroenterol. 38 (2000) 49-75
28. Burke W., Petersen G., Lynch P., Botkin J., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 277 (1997) 915-919
29. Jarvinen H.J., Mecklin J.P., and Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108 (1995) 1405-1411
30. Jarvinen H.J., Aarnio M., Mustonen H., Aktan-Collan K., Aaltonen L.A., Peltomaki P., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118 (2000) 829-834
31. Vasen H.F., Taal B.G., Nagengast F.M., Griffioen G., Menko F.H., Kleibeuker J.H., et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. Eur. J. Cancer 31A (1995) 1145-1148
32. Dove-Edwin I., Boks D., Goff S., Kenter G.G., Carpenter R., Vasen H.F., et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94 (2002) 1708-1712
33. Rodriguez-Bigas M.A., Boland C.R., Hamilton S.R., Henson D.E., Jass J.R., Khan P.M., et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J. Natl. Cancer Inst. 89 (1997) 1758-1762
34. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58 (1998) 5248-5257
35. Pistorius S.R., Kruppa C., Haas S., Plaschke J., Kruger S., Bulitta C.J., et al. Clinical consequences of molecular diagnosis in families with mismatch repair gene germline mutations. Int. J. Colorectal Dis. 15 (2000) 255-263
36. Plaschke J., Kruger S., Pistorius S., Theissig F., Saeger H.D., and Schackert H.K. Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int. J. Cancer 97 (2002) 643-648
37. Plaschke J., Kruppa C., Tischler R., Bocker T., Pistorius S., Dralle H., et al. Sequence analysis of the mismatch repair gene hMSH6 in the germline of patients with familial and sporadic colorectal cancer. Int. J. Cancer 85 (2000) 606-613
38. Kruger S., Plaschke J., Jeske B., Gorgens H., Pistorius S.R., Bier A., et al. Identification of six novel MSH2 and MLH1 germline mutations in HNPCC. Hum. Mutat. 21 (2003) 445-446
39. Kruger S., Plaschke J., Pistorius S., Jeske B., Haas S., Kramer H., et al. Seven novel MLH1 and MSH2 germline mutations in hereditary nonpolyposis colorectal cancer. Hum. Mutat. 19 (2002) 82
40. Plaschke J., Kruger S., Dietmaier W., Gebert J., Sutter C., Mangold E., et al. Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue. Hum. Mutat. 23 (2004) 285
41. Plaschke J., Ruschoff J., and Schackert H.K. Genomic rearrangements of hMSH6 contribute to the genetic predisposition in suspected hereditary non-polyposis colorectal cancer syndrome. J. Med. Genet. 40 (2003) 597-600
42. Pistorius S.R., Nagel M., Kruger S., Plaschke J., Kruppa C., Wehrmann U., et al. Combined molecular and clinical approach for decision making for surgery in HNPCC patients: a report on three cases in two families. Int. J. Colorectal Dis. 16 (2001) 402-407
43. Wells Jr. S.A., Chi D.D., Toshima K., Dehner L.P., Coffin C.M., Dowton S.B., et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 220 (1994) 237-247 [discussion 47-50]
44. Vasen H.F., van der Luijt R.B., Slors J.F., Buskens E., de Ruiter P., Baeten C.G., et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 348 (1996) 433-435
45. Peltomaki P., Gao X., and Mecklin J.P. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam. Can. 1 (2001) 9-15
46. Lin K.M., Shashidharan M., Thorson A.G., Ternent C.A., Blatchford G.J., Christensen M.A., et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J. Gastrointest. Surg. 2 (1998) 67-71
47. Wijnen J., de Leeuw W., Vasen H., van der Klift H., Moller P., Stormorken A., et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat. Genet. 23 (1999) 142-144
48. Lefebvre G., Allaire C., Jeffrey J., Vilos G., Arneja J., Birch C., et al. SOGC clinical guidelines. Hysterectomy. J. Obstet. Gynaecol. Can. 24 (2002) 37-61 [quiz 74-6]
49. Elit L., Esplen M.J., Butler K., and Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Can. 1 (2001) 149-156
50. Elit L., Rosen B., Goel V., McLaughlin J., Fung M.K., Shime J., et al. Prophylactic oophorectomy in Ontario. Fam. Can. 1 (2001) 143-148
51. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346 (2002) 1609-1615
52. Rebbeck T.R., Levin A.M., Eisen A., Snyder C., Watson P., Cannon-Albright L., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 91 (1999) 1475-1479
53. Moller P., Borg A., Evans D.G., Haites N., Reis M.M., Vasen H., et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int. J. Cancer 101 (2002) 555-559
54. van Roosmalen M.S., Verhoef L.C., Stalmeier P.F., Hoogerbrugge N., and van Daal W.A. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J. Clin. Oncol. 20 (2002) 2092-2100
55. Tiller K., Meiser B., Butow P., Clifton M., Thewes B., Friedlander M., et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol. Oncol. 86 (2002) 212-219
56. Lerman C., Hughes C., Croyle R.T., Main D., Durham C., Snyder C., et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev. Med. 31 (2000) 75-80
57. Meijers-Heijboer H., Brekelmans C.T., Menke-Pluymers M., Seynaeve C., Baalbergen A., Burger C., et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 21 (2003) 1675-1681
58. Botkin J.R., Smith K.R., Croyle R.T., Baty B.J., Wylie J.E., Dutson D., et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am. J. Med. Genet. 118A (2003) 201-209
59. Colgan T.J., Murphy J., Cole D.E., Narod S., and Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25 (2001) 1283-1289
60. Paley P.J., Swisher E.M., Garcia R.L., Agoff S.N., Greer B.E., Peters K.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol. Oncol. 80 (2001) 176-180
61. Lu K.H., Garber J.E., Cramer D.W., Welch W.R., Niloff J., Schrag D., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 (2000) 2728-2732
62. Leeper K., Garcia R., Swisher E., Goff B., Greer B., and Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 87 (2002) 52-56
63. Lynch H.T., and Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J. Clin. Oncol. 18 (2000) 19S-31S
64. Schmutzler R., Schlegelberger B., Meindl A., Gerber W.D., and Kiechle M. Counselling, genetic testing and prevention in women with hereditary breast- and ovarian cancer. Interdisciplinary recommendations of the consortium "Hereditary Breast- and Ovarian Cancer" of the German Cancer AiD. Zentralbl. Gynaekol. 125 (2003) 494-506
65. Vasen H.F., Haites N.E., Evans D.G., Steel C.M., Moller P., Hodgson S., et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur. J. Cancer 34 (1998) 1922-1926
66. Sauven P. Guidelines for the management of women at increased familial risk of breast cancer. Eur. J. Cancer 40 (2004) 653-665